...
首页> 外文期刊>International journal of endocrinology >The Potential Role of Gut Microbiota in the Prevention and Treatment of Lipid Metabolism Disorders
【24h】

The Potential Role of Gut Microbiota in the Prevention and Treatment of Lipid Metabolism Disorders

机译:肠道微生物群在预防和治疗脂质代谢障碍中的潜在作用

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Due to changes in lifestyle, diet structure, and aging worldwide, the incidence of metabolic syndromes such as hyperlipidemia, hypertension, diabetes, and obesity is increasing. Metabolic syndrome is considered to be closely related to cardiovascular disease and severely affects human health. In recent years, researchers have revealed that the gut microbiota, through its own or interacting metabolites, has a positive role in regulating metabolic syndrome. Therefore, the gut microbiota has been a new “organ” for the treatment of metabolic syndrome. The role has not been clarified, and more research is necessary to prove the specific role of specific strains. Probiotics are also believed to regulate metabolic syndromes by regulating the gut microbiota and are expected to become a new preparation for treating metabolic syndromes. This review focuses on the regulation of lipid metabolism disorders by the gut microbiota through the effects of bile acids (BA), short-chain fatty acids (SCFAs), bile salt hydrolase (BSH), and genes such as ABCG5 and ABCG8, FXR, NPC1L, and LDL-R.
机译:由于生活方式,饮食结构和世界老龄化的变化,代谢综合征如高脂血症,高血压,糖尿病和肥胖症的发生率正在增加。代谢综合征被认为与心血管疾病密切相关,严重影响人类健康。近年来,研究人员揭示了肠道微生物群,通过其自身或相互作用的代谢物在调节代谢综合征方面具有积极作用。因此,肠道微生物酵母是一种新的“器官”,用于治疗代谢综合征。作用尚未澄清,更多的研究是为了证明特定菌株的特定作用。还据信益生菌通过调节肠道微生物群,预计将成为治疗代谢综合征的新制剂。本综述致力于通过胆汁酸(BA),短链脂肪酸(SCFA),胆汁盐水解酶(BSH)和基因如ABCG5和ABCG8,FXR, NPC1L和LDL-R。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号